- 1 Title: Time-Varying Risk of Death After SARS-CoV-2-Infection in Long-Term Care Facility
- 2 Residents: A Matched Cohort Study
- 3 Short title: Time-Varying Mortality After SARS-CoV-2
- 4
- 5 Authors: Marcel Ballin, MSc<sup>1\*</sup>, John P.A. Ioannidis, MD, DSc<sup>2,3</sup>, Jonathan Bergman,

6 PhD<sup>1</sup>, Miia Kivipelto, MD, PhD<sup>4,5</sup>, Anna Nordström, MD, PhD<sup>1,6,7</sup>, Peter Nordström, MD,

 $7 \text{ Ph}\mathrm{D}^1$ 

8 ^ Indicating shared first authorship and equal contribution.

9 Affiliations: <sup>1</sup>Department of Community Medicine and Rehabilitation, Unit of Geriatric

10 Medicine, Umeå University, Umeå, Sweden. <sup>2</sup>Department of Medicine, Stanford University

11 School of Medicine, Stanford, CA, USA. <sup>3</sup>Department of Epidemiology and Population

12 Health, Stanford University School of Medicine, Stanford, CA, USA. <sup>4</sup>Division of Clinical

13 Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and

14 Society (NVS), Karolinska Institutet, Stockholm, Sweden . <sup>5</sup>Medical Unit Aging, Karolinska

15 University Hospital, Stockholm, Sweden. <sup>6</sup>School of Sport Sciences, UiT the Arctic

16 University of Norway, Tromsø, Norway. <sup>7</sup>Department of Public Health and Clinical

17 Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden

18 \*Correspondence: Marcel Ballin. Unit of Geriatric Medicine, Department of Community

19 Medicine and Rehabilitation, Umeå University, 90187 Umeå, Sweden. Phone:

20 +46735265380. E-mail: marcel.ballin@umu.se. Twitter: @Marcel Ballin

21 Disclosures: The authors received funding used for salaries from Foundation Stockholms

22 Sjukhem (MK), Academy of Finland (MK), Läkarsällskapet (MK), and the Swedish Research

23 Council (MK, AN, PN). The funders had no role in any part of this manuscript or the decision

24 to publish. The authors declare no conflicts of interest. The manuscript has been submitted

| ~ -  | • 1        |         | • , • | •    | 10.       |
|------|------------|---------|-------|------|-----------|
| 75 1 | nreviously | ac nrei | nrint | ın m | ed R v 1V |
| 23   | previously | as pre  | pinit |      | CUITAIV   |

- 26 (https://www.medrxiv.org/content/10.1101/2022.03.10.22272097v2).
- 27 Word count main text: 2859
- 28 Abstract word count: 300
- 29 Number of figures/tables: 2 figures, 1 table

30 Impact statement: We certify that this work is novel. This research adds to the literature by

- 31 showing there was no excess mortality observed in long-term care facility residents who
- 32 survived the acute SARS-CoV-2 infection, and that life expectancy of uninfected residents
- 33 was much lower than that of the general population of same age and sex. This has major
- 34 repercussions for estimation of years of life lost in infected long term care facility residents.

#### 35 Key points

- SARS-CoV-2 infection sharply increased mortality risk among residents of long-term
   care (LTC) facilities in the first month.
- After the first month, the mortality risk in infected residents rapidly returned to
   baseline and dropped below the mortality risk of uninfected controls, where it
   remained lower for 8 months of follow-up.
- Median survival of uninfected controls was 1.6 years, which was much lower than
  national life expectancy in Sweden at age 87.

#### 43 Why does this matter?

- Whereas LTC residents who recover from SARS-CoV-2 infection may be concerned
   about having residual debilitation caused by the infection, we found no excess
   mortality was in those who survived the acute infection.
- Because life expectancy of uninfected residents was much lower than that of the
- 48 general population of same age and sex, LTC resident status should be accounted for
- 49 in estimations of years of life lost.

### 50 Abstract

51 Background: SARS-CoV-2 confers high risk of short-term death in residents of long-term care (LTC) facilities, but longer-term risk among survivors is unclear. 52 53 **Methods:** We extended the follow-up period of a previous, propensity score-matched retrospective cohort study based on the Swedish Senior Alert register. N=3731 LTC residents 54 with documented SARS-CoV-2 until 15 September 2020 were matched to 3731 uninfected 55 56 controls using time-dependent propensity scores on age, sex, health status, comorbidities, and prescription medications. In a sensitivity analysis, matching included also geographical region 57 58 and Senior Alert registration time. The outcome was all-cause mortality over 8 months (until October 24, 2020). The absolute risk of death was examined using Kaplan-Meier plots. 59 Hazard ratios (HR) for death over time were estimated using flexible parametric models with 60 61 restricted cubic splines. Cox regression was used to estimate HRs and 95% confidence intervals (CIs) in 30-day intervals of follow-up until 210 days. 62 63 **Results:** The median age was 87 years and 65% were women. Excess mortality was highest 5 64 days after documented infection (HR 19.1, 95% CI, 14.6-24.8), after which excess mortality 65 decreased. From the second month onwards, mortality rate became lower in infected residents than controls. The HR for death during days 61-210 of follow-up was 0.41 in the main 66 67 analysis (95% CI, 0.34-0.50) and 0.76 (95% CI, 0.62-0.93) in the sensitivity analysis. Median survival of uninfected controls was 1.6 years, which was much lower than the national life 68 expectancy in Sweden at age 87 (5.05 years in men, 6.07 years in women). 69 Conclusions: No excess mortality was observed in LTC residents who survived the acute 70 71 SARS-CoV-2 infection. Life expectancy of uninfected residents was much lower than that of 72 the general population of the same age and sex. This suggests that LTC resident status should be accounted for in years-of-life-lost estimates for COVID-19 burden of disease calculations. 73 Keywords: COVID-19, SARS-CoV-2, death, long-term care facilities, mortality 74

## 75 Introduction

| 76 | During the coronavirus disease 2019 (COVID-19) pandemic, many of the   |
|----|--|
| 77 | COVID-19 deaths that occurred in high-income countries were seen in long-term care (LTC)                         |
| 78 | facilities, <sup>1</sup> where case fatality rates were 10-40% or even higher. <sup>2,3</sup> We have previously |
| 79 | reported that 30-day mortality in Swedish LTC was 40% in residents infected with severe                          |
| 80 | acute respiratory syndrome coronavirus 2 (SARS-CoV-2) versus 6% in matched, non-infected                         |
| 81 | controls in the first wave of the pandemic. <sup>4</sup> A natural follow-up question to ask is whether          |
| 82 | SARS-CoV-2 also increases the risk of death beyond the acute period of 30 days, i.e. whether                     |
| 83 | it has long-term effects on mortality in LTC residents who recover from infection. A major                       |
| 84 | concern is that LTC residents who recover from SARS-CoV-2 infection may have residual                            |
| 85 | debilitation caused by the infection. If so, this may affect also their life expectancy beyond the               |
| 86 | acute phase of the infection. Moreover, it would be interesting to estimate the loss of life                     |
| 87 | expectancy in LTC residents infected with SARS-CoV-2. We set out to answer these                                 |
| 88 | questions by extending the follow-up period in our previous analysis from 30 days to 8                           |
| 89 | months.  |

### 90 Methods

### 91 Study design and population

The present study offers extended follow-up on a propensity score-matched 92 retrospective cohort study.<sup>4</sup> The basic study design and of the selection of exposed (infected) 93 94 and unexposed (uninfected control) residents has been described in detail previously in the publication presenting 30-days of follow-up.<sup>4</sup> In brief, data on Swedish LTC residents were 95 obtained from Senior Alert, a database of health assessments performed in older adults aged 96 97 ≥65 years.<sup>5</sup> All residents of LTC facilities in Sweden registered in Senior Alert were eligible to be considered. Senior Alert collects health data on various conditions in adults aged  $\geq 65$ 98 years. Senior Alert captures an estimated 73% of all Swedish LTC facility residents. This 99

study was approved by the Swedish Ethical Review Authority (no. 2020-02552), which
waived the informed consent requirement given the retrospective nature of the study. The

study was performed in accordance with the Declaration of Helsinki.

## 103 Cohort construction and matching

We selected LTC residents who had a record in Senior Alert from 2019 or 2020; the latest record during these years was used, whenever there were multiple records. Among these, we identified 3731 LTC residents with a documented SARS-CoV-2 infection until September 15, 2020. We excluded SARS-CoV-2 infected residents that did not have a record in Senior Alert within a year prior to date of testing or confirmed infection (whichever came first or was available) and those where dates of testing and confirmed infection were both unavailable. Data on SARS-CoV-2 infections were obtained from the national SmiNet

111 registry to which reporting is mandatory according to Swedish law.

112 Each infected resident was matched 1:1 to a control resident on age, sex, body mass index, health status, comorbidity, and prescription medication use, using time-dependent 113 114 propensity scores. This enables matching when the exposure (date of documented SARS-115 CoV-2 infection) do not coincide with the time of cohort entry (date of Senior Alert record). 116 With time starting at the date of the Senior Alert record, a Cox model calculated a propensity 117 score for the propensity to contract SARS-CoV-2 based on all variables shown in Supplemental Table 1. Each infected resident was matched to the control with the closest 118 propensity score among those who were still alive when the SARS-CoV-2 case occurred 119 120 (counting time since the Senior Alert date). Matching was done sequentially, starting with the first case (smaller number of days since cohort entry) and proceeding with cases with 121 122 increasingly larger number of days since cohort entry. Diagnoses and medications were used as time-varying covariates in the Cox regression model. Information on comorbidities was 123 obtained from the Swedish National Patient Register and for cancer from the Swedish Cancer 124

Register. Information on recent use of medications (prescriptions in 2019-2020) came from Senior Alert and the Swedish Prescribed Drug Register. In addition, in order to conduct a sensitivity analysis to examine whether the results were confounded by secular trends and geographic variations in mortality, we performed an additional matching which included also the geographical region (21 categories) and the date (year and month) of Senior Alert registration. Data linkage across registers were performed using pseudo-anonymised Personal Identification Numbers.

132 Outcome

The study outcome was all-cause mortality (until October 24, 2020). These data were obtained from the national Swedish Cause of Death Register. While in our previous study we only assessed 30-day mortality,<sup>4</sup>, the extension to 8 months in the present study allows to get a more complete picture of the mortality risk of this frail population, while at the same time it largely excludes the subsequent waves and also the COVID-19 vaccination period which may have further affected mortality risk in this population.

### 139 Statistical analysis

140 In both the main and sensitivity analyses for death risk, all-cause mortality was considered as the outcome of interest and the starting date for follow-up was the SARS-CoV-141 142 2 documentation date in cases and the corresponding date (in days since cohort entry) in controls. Follow-up time in days was calculated as censor date (24 October 2020 or death 143 whichever came first) minus baseline date + 1 day. This was done so that the baseline date 144 could also be included in the follow-up time and analysis (thus, a person would be able to die 145 146 on the same date as they were documented to be infected). The absolute risk of death was 147 examined using Kaplan-Meier plots. The hazard ratio (HR) for death was plotted over time using flexible parametric models with restricted cubic splines (4 knots in default positions). 148 HRs and 95% confidence intervals (CIs) were also estimated using Cox regression for 30-day 149

intervals of follow-up until 210 days. To adjust for matching, we calculated 95% CIs in the 150 151 Cox models and the flexible parametric models using robust standard errors. All analyses 152 were performed using Stata MP version 16.1 for Mac (StataCorp, College Station, TX). **Results** 153 154 **Baseline characteristics** 155 Baseline characteristics are shown in Supplemental Table 1. The median age was 87 years, 156 65% were women, and comorbidities were common. In the main analysis, median 157 (interquartile range [IQR] baseline date for infected residents was 27 Apr 2020 (10 Apr to 22 158 May), median (maximum) follow-up was 129 (246) days and there were 1713 deaths. For 159 controls, median (IQR) baseline date was 12 Apr 2020 (16 Dec 2019 to 30 Jun 2020), median (maximum) follow-up was 146 (641) days and there were 899 deaths. In the sensitivity 160 161 analysis, for infected residents, median (IQR) baseline date was 26 Apr 2020 (IQR 10 Apr to 162 21 May), median (maximum) follow-up was 130 (246) days and there were 1640 deaths. For 163 controls, median (IQR) baseline date was 28 Apr 2020 (9 Apr to 23 May), median 164 (maximum) follow-up was 173 (249) days and there were 536 deaths. The median age was 87 165 years, 65% were women, and comorbidities were common (Supplemental Table 1). 166 **Mortality analyses** 167 As previously reported, SARS-CoV-2 was associated with a sharp, early increased risk of death: 40% versus 6% within 30 days (1487/3731 versus 211/3731). 168 169 However, extending the follow-up period showed that the risk soon plateaued (Figure 1A). Similar results were seen in the sensitivity analysis (Figure 1B). 170 171 Survival of controls at 210 days was 74.3% (72.6%-75.9%) in the main analysis 172 and 82.9% (81.3%-84.4%) in the sensitivity analysis. Median survival of controls was 577 days. Median survival was also 577 days among the controls who were matched to the 1487 173

174 infected residents who died in the first month. Survival of these 1487 controls was similar to

the survival of the remaining 2242 controls, for example their survival at 210 days was 72.5%
versus 75.4%.

177 In the main analysis, peak HR (19.1 (95% CI, 14.6-24.8)) occurred at 5 days after documented infection. HR was high in the first month, decreased below 1.0 early in the 178 second month, and remained below 1.0 for the remaining duration of follow-up (Figure 2a). 179 180 In the sensitivity analysis, peak HR was 21.5 (95% CI, 15.9-29.2). Again, HR decreased 181 sharply but took a bit longer to drop below 1.0 (after the second month) and remained below 182 1.0 afterwards (Figure 2b). In the main analysis, for 0-30 days, there were 1487 deaths among infected 183 184 residents (17.57 deaths per 1000 person-days) versus 211 in uninfected controls (1.88 deaths per 1000 person-days), resulting in a HR of 8.81 (7.64-10.15). For 31-60 days, there were 93 185 186 deaths (1.42 per 1000 person-days) versus 144 (1.42 per 1000 person-days) (HR 1.00 (0.77-187 1.30)). For 61-90 days the respective numbers were 33 (0.55) versus 121 (1.38) (HR 0.38 (0.26-0.55)). For 91-120 days, the respective numbers were 38 (0.63) versus 126 (1.72) (HR 188 189 0.36 (0.25-0.52)). A similar pattern was seen for 121-150 days (HR, 0.52 (0.36-0.76)), 151-190 180 days (HR 0.47 (0.28-0.79)), and 181-210 days (HR 0.29 (0.10-0.83)). 191 During the 61-210 days follow-up, there were 133 deaths among infected 192 residents (0.58 per 1000 person-days) versus 420 deaths among the uninfected controls (1.37 193 per 1000 person-days), with the HR being 0.41 (0.34-0.50). In the sensitivity analysis, during 61-210 days of follow-up, there were 131 deaths (0.59 per 1000 person-days) in infected 194 195 versus 278 deaths (0.78 per 1000 person-days) in controls, with the HR being 0.76, 95% CI, 196 0.62-0.93).

# 197 **Discussion**

In this extended follow-up analysis of mortality in SARS-CoV-2-infected versus
uninfected control LTC residents, we found that mortality risk peaked during the first week of

documented infection, after which it rapidly decreased. Mortality remained elevated for the 200 201 first month after infection, but then reverted back to baseline levels (i.e., control levels) before it dropped below baseline levels, where it remained at low levels for the remaining duration of 202 203 follow-up (up to 8 months). These results suggest that SARS-CoV-2 does not reduce the life expectancy of LTC residents who survive the acute period of the disease. Despite concerns 204 205 that infected residents who survive may have persistent residual debilitation that might 206 enhance their subsequent death risk, we saw the opposite: death risk decreased in longer-term 207 follow-up. This suggests that deaths due to COVID-19 in LTC facilities in Sweden during the 208 first wave probably resulted in average loss of life expectancy of less than 1.6 years on 209 average. This figure is much lower than the life expectancy in the general Swedish population, which in 2019 was 5.05 years for men and 6.07 years for women at the age of 87 210 211 (the median age in our study).<sup>7</sup>

212 Calculations of burden of disease due to COVID-19 often use age- and sexadjusted life expectancies to calculate years-of-life-lost; however, without properly 213 214 accounting for LTC residence and general health. Our findings suggest that such an approach 215 can yield massively inflated estimates.<sup>8</sup> Adjustment for comorbidities has been shown to decrease the number of years-of-life-lost in some studies.<sup>9-11</sup> However, the change is typically 216 217 modest (e.g. in the range of 1 years) and much smaller than what we observed in the LTC 218 resident population that we evaluated. It is possible that in most studies, information on comorbidities is not available in sufficient granularity and accuracy regarding severity. E.g. 219 220 "kidney disease" would carry very different risk connotations depending on the stage and 221 severity. LTC resident status is a surrogate for increased frequency and severity of many 222 comorbidities and of overall frailty. Therefore, it should be taken into account as a first 223 correction for any years-of-life-lost estimates for COVID-19 burden of disease calculations.

Calculations accounting for LTC status and also properly adjusting for 224 225 comorbidities and their severity may also lead to much lower estimates than some other increasingly used approaches such as the Global Burden of Disease Reference Life Table<sup>12</sup> -226 227 also known as Theoretical Minimum Risk Life Table. This life table is an "aspirational" construct: it assumes an idealized situation with very low risk of death. According to this 228 table, life expectancy is 88.9 years at birth, 9.99 years at age 85, 5.92 years at age 90, and 229 5.92 years at age 95.<sup>13</sup> Using this popular aspirational life table would probably overestimate 230 by 5-10-fold the years-of-life-lost for SARS-CoV-2-deceased residents in LTC facilities. 231 232 Aspirational life tables have been promoted as a way to standardize burden of disease 233 calculations across different countries. However, in the case of diseases like COVID-19 they 234 could lead to grossly misleading inferences.

235 Estimates of survival in residents of LTC facilities preceding the COVID-19 236 pandemic also agree with very limited median survival of nursing home residents, e.g. 541 days in one study in the United Kingdom<sup>14</sup> and 2 years in a study of residential care entrants 237 in New Zealand.<sup>15</sup> In Sweden, previously published data<sup>16</sup> on the survival of elderly people 238 239 who moved into institutionalized care in an area of Stockholm (N=1103) suggested that, on average, the median survival after moving to institutionalized care declined between 2006 and 240 241 2012 from 764 to 595 days. For the lower percentiles, the decrease was very large, e.g. for the 242 30th percentile, the length of stay declined from 335 days in 2006 to 119 days in 2012, and in 2012 10% died within just 8 days. A widening survival gap (due to shortening survival in 243 nursing home residents) versus community-dwelling elderly has also been documented in a 244 10-year study in England.<sup>17</sup> Another study<sup>18</sup> evaluated all deaths in people >67 years old in 245 November 2015 in Sweden and focused on the 2 years prior to death. Women used LTC for 246 247 15.6 months and men for 14.1 months out of 24 these months. The length of stay in institutional care was 7.2 and 6.2 months, respectively. These survival data for LTC residents 248

are in line with the estimated median survival of controls in our study, thus further validatingthe median survival in residents of LTC facilities is very limited.

We should acknowledge that there can be large heterogeneity in survival in 251 252 different LTC facilities. Some LTC facilities admit mostly residents with known limited lifeexpectancy (mostly for palliative care), while others may be institutions that admit mostly 253 254 older adults who are quite healthy or have limited health problems with substantial life-255 expectancy. A systematic review has found that across 6 cohort studies, the mortality rate 256 within 6 months of admission to a nursing home ranged from 0% to 34% (median 20.2%).<sup>19</sup> In our analysis, we could not include data on the features of each LTC facility (e.g. whether it 257 258 focused on palliative care) and we could not match infected residents with uninfected residents from the same facility. Nevertheless, the control groups both in the main and in the 259 260 sensitivity analysis seem to have median survival that is entirely compatible with the literature 261 on LTC residents and their overall limited expected survival, on average.

Some additional caveats should be discussed. Our data pertain to fatalities 262 263 during the first wave of COVID-19 and until the fall of 2020. The first wave was the most 264 devastating in most high-income countries, with a few exceptions (e.g. Australia).<sup>20,21</sup> The relatively lower proportion of fatalities in LTC residents in subsequent waves may reflect a 265 266 combination of multiple factors: high levels of prior infection (seroprevalence studies have 267 found 5-10 times higher infection rates in LTC facilities than in the general population in the first wave),<sup>22-24</sup> better protection of nursing homes, more extensive testing, widespread use of 268 vaccination in 2021,<sup>21</sup> and the possibility that the sickest individuals were the first to 269 succumb.<sup>25</sup> Moreover, the lower risk of death after the first month post-infection versus the 270 271 uninfected controls should not be interpreted as a sign that SARS-COV-2 infection causally 272 decreases the risk of death during long-term follow-up, as it probably reflects mostly a selection process (residents who died in the first month were probably more sick and 273

debilitated before infection, while those surviving probably had better life expectancy). 274 275 Finally, we cannot exclude the possibility that some controls may have been 276 asymptomatically infected but the infection remained unnoticed due to limited testing, 277 especially in the early weeks of the pandemic. With more systematic testing after the end of the first wave and with limited epidemic activity during the late spring and summer of 2020, it 278 279 is unlikely that infections in controls were missed in that period, let alone that these infections 280 would shorten the survival of the control groups. As above, the observed limited survival of 281 the control groups is entirely in line with data on residents of LTC facilities in the absence of 282 COVID-19 from Sweden and elsewhere. In further support of our findings, excess death 283 calculations for Sweden for 2020 and also for the entire pandemic period to end of 2021 and early 2022 show very limited excess deaths, if at all.<sup>26,27</sup> This pattern is entirely congruent 284 285 with the possibility that many/most residents who died of SARS-CoV-2 in the first wave had 286 very limited life expectancy. Therefore, they would not contribute to excess death 287 calculations, if excess deaths are assessed over 1-2 years downstream. 288 Allowing for these caveats, the major strength of our study is that it uses on 289 large databases with nationwide coverage. Even so, similar analyses should also be performed 290 in other countries because the health status of LTC residents may be different and with 291 assessments covering also the vaccination period for a complete picture of the COVID-19 292 pandemic.<sup>28</sup> This will allow to obtain more solid evidence on both the years-of-life-lost over 293 2020-2022, as well as insights about the long-term outcomes of SARS-CoV-2-infected 294 residents of various types of LTC facilities who survived and recovered from the acute 295 infection.

296 Acknowledgments

| 297 | Confli | ict of Interest: The authors received funding used for salaries from Foundation            |
|-----|--------|--|
| 298 | Stockł | nolms Sjukhem (MK), Academy of Finland (MK), Läkarsällskapet (MK), and the                 |
| 299 | Swedi  | sh Research Council (MK, AN, PN). The authors declare no conflicts of interest.            |
| 300 | Autho  | or Contributions: Concept and design: MB, JPI, JB, PN, Acquisition, analysis, or           |
| 301 | interp | retation of data: All authors. Drafting of the manuscript: MB, JPI. Critical revision of   |
| 302 | the ma | nuscript for important intellectual content: All authors. Statistical analysis: MB and JB. |
| 303 | Superv | vision: PN, JPI.   |
| 304 | Spons  | or's Role: The funders had no role in any part of this manuscript or the decision to       |
| 305 | publis | h.   |
| 306 |        |  |
| 307 | Refei  | rences   |
| 308 | 1.     | Comas-Herrera A, Zalakaín J, Lemmon E, Henderson D, Litwin C, Hsu A, et al.                |
| 309 |        | Mortality associated with COVID-19 in care homes: international evidence. Article in       |
| 310 |        | LTCcovid.org, International Long-Term Care Policy Network, CPEC-LSE, 14                    |
| 311 |        | October2020.   |
| 312 | 2.     | Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause           |
| 313 |        | 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021;           |
| 314 |        | 181: 439-448.  |
| 315 | 3.     | Murti M, Goetz M, Saunders A, Sunil V, Guthrie JL, Eshaghi A, Zittermann S,                |
| 316 |        | Teatero S, Fittipaldi N, Rilkoff H, Gubbay JB, Garber G, Callery S, Holt AM,               |
| 317 |        | Noseworthy AL. Investigation of a severe SARS-CoV-2 outbreak in a long-term care           |
| 318 |        | home early in the pandemic. CMAJ. 2021 May 10;193(19):E681-E688.                           |
| 319 | 4.     | Ballin M, Bergman J, Kivipelto M, Nordström A, Nordström P. Excess Mortality               |
| 320 |        | After COVID-19 in Swedish Long-Term Care Facilities. J Am Med Dir Assoc. 2021              |
| 321 |        | Aug;22(8):1574-1580.e8.  |

- 322 5. Edvinsson J, Rahm M, Trinks A, Hoglund PJ. Senior alert: A quality registry to
- 323 support a standardized, structured, and systematic preventive care process for older
- adults. Qual Manag Health Care. 2015;24:96–101.
- 3256. Brooke HL, Talbäck M, Hörnblad J. The Swedish cause of death register. Eur J
- **326** Epidemiol. 2017;32:765–773.
- 327 7. <u>https://www.statistikdatabasen.scb.se/pxweb/en/ssd/START\_BE\_BE0101\_BE010</u>
- 328 <u>1I/LivslangdEttariga/</u>, last accessed March 3, 2022
- 8. Ioannidis JPA. Over- and under-estimation of COVID-19 deaths. Eur J Epidemiol.
- **330** 2021 Jun;36(6):581-588.
- 9. Ferenci T. Different approaches to quantify years of life lost from COVID-19. Eur J
  Epidemiol. 2021;36:589–597.
- 10. von der Lippe E, Devleesschauwer B, Gourley M, et al. Reflections on key

methodological decisions in national burden of disease assessments. Arch Public
Health. 2020;78:137.

- 11. Hanlon P, Chadwick F, Shah A, et al. COVID-19—exploring the implications of long-
- term condition type and extent of multimorbidity on years of life lost: a modelling
- 338 study. Wellcome Open Res 2021;5:75.
- 33912. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204
- countries and territories, 1990–2019: a systematic analysis for the Global Burden of
- 341 Disease Study 2019. The Lancet. 2020;396:1204–1222.
- 342 13. Global Burden of Disease Study 2019 Reference Life Table,
- 343 <u>http://ghdx.healthdata.org/record/ihme-data/global-burden-disease-study-2019-gbd-</u>
- 344 <u>2019-reference-life-table</u>, last accessed March 8, 2022.

| 345 | 14. Rothera IC, Jones R, Harwood R, Avery AJ, Waite J. Survival in a cohort of social   |
|-----|---|
| 346 | services placements in nursing and residential homes: factors associated with life      |
| 347 | expectancy and mortality. Public Health. 2002 May;116(3):160-5.                         |
| 348 | 15. Broad JB, Lumley T, Ashton T, Davis PB, Boyd M, Connolly MJ. Transitions to and     |
| 349 | from long-term care facilities and length of completed stay: Reuse of population-based  |
| 350 | survey data. Australas J Ageing. 2017 Jun;36(2):E1-E7.                                  |
| 351 | 16. Schön P, Lagergren M, Kåreholt I. Rapid decrease in length of stay in institutional |
| 352 | care for older people in Sweden between 2006 and 2012: results from a population-       |
| 353 | based study. Health Soc Care Community. 2016 Sep;24(5):631-8.                           |
| 354 | 17. Espuny Pujol F, Hancock R, Morciano M. Trends in survival of older care home        |
| 355 | residents in England: A 10-year multi-cohort study. Soc Sci Med. 2021                   |
| 356 | Aug;282:113883.   |
| 357 | 18. Meinow B, Wastesson JW, Kåreholt I, Kelfve S. Long-term care use during the last    |
| 358 | 2 years of life in Sweden: implications for policy to address increased population      |
| 359 | aging. J Am Med Dir Assoc. 2020 Jun;21(6):799-805.                                      |
| 360 | 19. Ferrah N, Ibrahim JE, Kipsaina C, Bugeja L. Death following recent admission into   |
| 361 | nursing home from community living: A systematic review into the transition process.    |
| 362 | J Aging Health. 2018 Apr;30(4):584-604.   |
| 363 | 20. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Second versus first wave of      |
| 364 | COVID-19 deaths: Shifts in age distribution and in nursing home fatalities. Environ     |
| 365 | Res. 2021 Apr;195:110856.   |
| 366 | 21. Pastorino R, Pezzullo AM, Villani L, Causio FA, Axfors C, Contopoulos-Ioannidis     |
| 367 | DG, Boccia S, Ioannidis JPA. Change in age distribution of COVID-19 deaths with         |
| 368 | the introduction of COVID-19 vaccination. Environ Res. 2022 Mar;204(Pt C):112342.       |
|     |   |

| 369 | 22. Candel FJ, Barreiro P, San Román J, Del Mar Carretero M, Sanz JC, Pérez-Abeledo        |
|-----|--|
| 370 | M, et al. The demography and characteristics of SARS-CoV-2 seropositive residents          |
| 371 | and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS        |
| 372 | study. Age Ageing. 2021;50(4):1038-47.   |
| 373 | 23. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, et al. Prevalence    |
| 374 | of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. J Clin          |
| 375 | Med. 2020;9(9).  |
| 376 | 24. Krutikov M, Palmer T, Tut G, Fuller C, Shrotri M, Williams H, et al. Incidence of      |
| 377 | SARS-CoV-2 infection according to baseline antibody status in staff and residents of       |
| 378 | 100 long-term care facilities (VIVALDI): a prospective cohort study. Lancet Healthy        |
| 379 | Longevity. 2021;2(6):e362-e70.   |
| 380 | 25. Levi M, Cipriani F, Romeo G, Balzi D. Analysis of the excess mortality and factors     |
| 381 | associated with deaths from COVID-19 versus other causes in Central Tuscany (Italy)        |
| 382 | in 2020. Epidemiol Prev. 2021 Nov-Dec;45(6):496-503.                                       |
| 383 | 26. Kowall B, Standl F, Oesterling F, Brune B, Brinkmann M, Dudda M, Pflaumer P,           |
| 384 | Jöckel KH, Stang A. Excess mortality due to Covid-19? A comparison of total                |
| 385 | mortality in 2020 with total mortality in 2016 to 2019 in Germany, Sweden and Spain.       |
| 386 | PLoS One. 2021 Aug 3;16(8):e0255540.   |
| 387 | 27. Human Mortality Database, mortality.org, last accessed May 1, 2022.                    |
| 388 | 28. Ioannidis JP. The end of the COVID-19 pandemic. Eur J Clin Invest 2022; Mar            |
| 389 | 28:e13782.   |
| 390 |  |
| 391 | Figure legends:  |
| 392 | Figure 1. Risk of death in residents with SARS-CoV-2 and controls in the main analysis (A) |

and in the sensitivity analysis (B). The coloured areas show the 95% confidence interval.

- 394 Figure 2. Hazard ratio for death in residents with SARS-CoV-2, as compared with controls in
- 395 (A) the main analysis and (B) the sensitivity analysis. The coloured areas show the 95%
- 396 confidence interval



